Changes in natural immunity during the course of HIV-1 infection

Clinical and Experimental Immunology

Volumn 93, Issue 2, 1993, Pages 142-148

  Brenner, B G ^a   Gryllis, C ^a   Gornitsky, M ^a   Wainberg, M A ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

AIDS; CD8 and CD56; lymphocyte subsets; lymphokine activated killer cells; natural killer cells

Indexed keywords

CD8 ANTIGEN; INTERLEUKIN 2;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE SUBPOPULATION; LYMPHOKINE ACTIVATED KILLER CELL; NATURAL KILLER CELL; PRIORITY JOURNAL;

EID: 0027274884     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.1993.tb07956.x     Document Type: Article

References (49)

1. Adv Immunol Trinchieri 47 187 1989 10.1016/S0065-2776(08)60664-1 Biology of natural killer cells
2. Blood Robertson 76 2421 1991 10.1182/blood.V76.12.2421.2421 Biology and clinical relevance of natural killer cells
3. Adv Immunol Ritz 42 181 1988 10.1016/S0065-2776(08)60845-7 Characterization of functional surface structures on human natural killer cells
4. J Leukocyte Biol Brenner 46 75 1989 10.1002/jlb.46.1.75 Natural killer cell function in patients with acquired immunodeficiency syndrome and related diseases
5. J Leukocyte Biol Brenner 50 628 1991 10.1002/jlb.50.6.628 The role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases
6. Lancet Weinhold i 902 1988 10.1016/S0140-6736(88)91713-8 Cellular anti-gp 120 cytolytic reactivities in HIV-1+ individuals
7. J Virol Rivière 63 2270 1989 10.1128/jvi.63.5.2270-2277.1989 Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals. Distinct types of effector cells mediate killing of targets expressing gag and env proteins
8. J Immunol Weinhold 142 3091 1989 HIV-1 gpl20-mediated immune suppression and lymphocyte destruction in the absence of viral infection
9. Anticancer Res Brenner 11 969 1991 Differential effects of chemotherapy-induced and HIV-1 induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations
10. AIDS Res Hum Retroviruses Vuillier 4 121 1988 10.1089/aid.1988.4.121 Selective depletion of low-density CD8+, CD16+ lymphocytes during HIV infection
11. AIDS Landay 4 479 1990 10.1097/00002030-199006000-00001 Application of flow cytometry to the study of HIV function
12. Biotherapy Schwartz 2 119 1990 10.1007/BF02173452 Interleukin-2 in the treatment of HIV disease
13. Biochim Biophys Acta Grimm 565 267 1986 Human lymphokine-activated killer cells (LAK cells) as a potential immunotherapeutic modality
14. J Natl Cancer Inst Ortaldo 80 999 1988 10.1093/jnci/80.13.999 Human natural lymphocyte effector cells. Definition, analysis of activity and clinical effectiveness
15. Nat Immun Cell Growth Regul Skibber 6 291 1987 Human lymphokine-activated killer cells. Further characterization of the precursor and effector cell
16. J Exp Med Ortaldo 164 1193 1986 10.1084/jem.164.4.1193 Lymphokine-activated killer cells. Analysis of progenitors and effectors
17. J Exp Med Phillips 164 814 1986 10.1084/jem.164.3.814 Dissection of the lymphokine-activated phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis
18. Eur J Cancer Clin Oncol Ozaki 24 1055 1988 10.1016/0277-5379(88)90159-9 The difference in surface phenotypes between cytotoxic lymphocytes induced in vivo by systemic administration of human recombinant interleukin-2 and lymphokine-activated killer cells induced in vitro
19. Cancer Res Weil-Hillman 49 3680 1989 Lymphokine-activated killer activity induced by in vivo inlerleukin-2 therapy: predominant role for lymphocytes with increased expression of CD2 and Leu 19 antigens but negative expression of CD16 antigens
20. Cancer Res Gambacorti-Passenni 49 5230 1989 Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin-2: possible role of lymphokine-activated killer cell infusion in the in vivo induced activation
21. J Immunol McMannis 140 1335 1988 In vivo effects of recombinant IL-2. I. Isolation of circulating Leul9+ lymphokine-activated killer effector cells from cancer patients receiving recombinant IL-2
22. J Clin Oncol Phillips 5 1933 1987 10.1200/JCO.1987.5.12.1933 In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing recombinant interleukin-2 and LAK cell therapy
23. AIDS Gryllis 4 1205 1990 10.1097/00002030-199012000-00004 Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders
24. Clin Exp Immunol Gryllis 89 356 1992 10.1111/j.1365-2249.1992.tb06962.x Increased LAK activity against HIV-infected cell lines in HIV-1 individuals
25. Cancer Brenner 58 895 1986 10.1002/1097-0142(19860815)58:4<895::AID-CNCR2820580416>3.0.CO;2-A Peripheral blood natural killer cell activity in human breast cancer patients and its modulation by T cell growth factor and autologous plasma
26. J Clin Immunol Pross 1 51 1981 10.1007/BF00915477 Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IX: The quantitation of natural killer cell activity
27. Cancer Res Brenner 42 3187 1982 Monoclonal antibodies to human lung tumor antigens demonstrated by immunofluorescence and immunoprecipitation
28. Cell Immunol Stine 136 165 1991 10.1016/0008-8749(91)90391-N The effect of AZT on in vitro lymphokine-activated killer (LAK) activity in human immunodeficiency virus type-1 (HIV-I) infected individuals
29. Anticancer Res Gryllis 10 1428 1990 Differential mechanisms for suppression of natural killer (NK) and lymphokine activated killer (LAK) cell-mediated cytolytic responses by lymphocytes isolated from breast cancer patients on chemotherapy and AIDS subjects
30. J Immunol Ruscetti 136 3619 1986 Analysis of effector mechanisms against HTLV-I and HTLV-III/LAV infected lymphoid cells
31. Clin Immunol Immunopathol Chin 53 449 1989 10.1016/0090-1229(89)90007-X Lymphokine-activated killer cells in primary immunodeficiencies and acquired immunodeficiency syndrome
32. J Clin Microbiol Rappocciolo 27 41 1989 10.1128/jcm.27.1.41-48.1989 Association of alpha interferon production and natural killer cell lysis of U937 cells infected with human immunodeficiency virus
33. J Invest Dermatol Azogui 97 425 1991 10.1111/1523-1747.ep12481140 Tumor-infiltrating CD3 NK cells are more effective than CD3+ T cells in killing autologous melanoma cells
34. Cellular Immunol Ortaldo 136 486 1991 10.1016/0008-8749(91)90369-M Comparative studies of CD3− and CD3+ CD56+ cells: examination of morphology, function. T cell receptor rearrangement, and poreforming protein expression
35. J Immunol Abo 129 1752 1982 Characterization of HNK+ Leu7−human lymphocytes. Two distinct phenotypes of human NK cells with different cytotoxic capability
36. J Virol Chehimi 65 1812 1991 10.1128/jvi.65.4.1812-1822.1991 In vitro infection of natural killer cells with different human immunodeficiency virus type 1 isolates
37. Clin Exp Immunol Bandyopadhyay 79 430 1990 10.1111/j.1365-2249.1990.tb08107.x Natural killer cell-mediated lysis of T cell lines chronically infected with HIV-1
38. Clin Exp Immunol Levacher 90 376 1992 10.1111/j.1365-2249.1992.tb05854.x The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome—staging and prognostic value
39. Nat Immun Cell Growth Regul Cauda 9 366 1990 Inhibition of lymphokine-activated killer activity during HIV infection: role of HIV-1 gp4l synthetic peptides
40. J Immunol Katz 139 55 1987 Mechanism of defective NK cell activity in patients with AIDS and AIDS-related complex. II Normal ADCC mediated by effector cells defective in NK cytotoxicity
41. J Immunol Sirianni 140 2565 1988 Mechanism of defective natural killer cell activity in patients with AIDS is associated with defective distribution of tubulin
42. AIDS Walker 4 177 1990 10.1097/00002030-199003000-00001 Cytotoxic lymphocytes against HIV
43. AIDS Nixon 5 1049 1991 Cytotoxic T-cell recognition of HIV proteins and peptides
44. J Immunol Tyler 144 3375 1990 Alterations in antibody-dependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects
45. Lancet Weinhold 1 902 1988 10.1016/S0140-6736(88)91713-8 Cellular anti-gp120 cytolytic reactivities in HIV-I seropositive individuals
46. AIDS Res Human Retroviruses Mclder 6 1011 1990 10.1089/aid.1990.6.1011 Cytotoxic activity against HIV-infectcd monocytes by recombinant interleukin-2-activated natural killer cells
47. Ann Int Med Fauci 114 678 1991 10.7326/0003-4819-114-8-678 Immunopathogenic mechanisms in human immunodeficiency virus (HIV) infection
48. Science Riddell 257 238 1992 10.1126/science.1352912 Restoration of viral immunity in immunodeficient human by the adoptive transfer of T-cell clones
49. Characteristics of ex vivo propagated autologous CD8+ T cells used in the treatment of patients infected with human immunodeficiency virus Whiteside A35 1992